Institutional investors purchased a net $511.5 thousand shares of MYGN during the quarter ended December 2016 and now own 122.40% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CAMBER CAPITAL MANAGEMENT LLC Bought 4.1 Million shares of Myriad Genetics Inc
CONSONANCE CAPITAL MANAGEMENT LP Bought 1.5 Million shares of Myriad Genetics Inc
RUSSELL INVESTMENT MANAGEMENT LL... Bought 1.1 Million shares of Myriad Genetics Inc